Northern Trust’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-391,781
| Closed | -$1.45M | – | 4308 |
|
|
2017
Q4 | $1.45M | Sell |
391,781
-5,101
| -1% | -$20.9K | ﹤0.01% | 3286 |
|
|
2017
Q3 | $1.62M | Buy |
396,882
+14,413
| +4% | +$55.1K | ﹤0.01% | 3289 |
|
|
2017
Q2 | $1.42M | Buy |
382,469
+308,270
| +415% | +$1.22M | ﹤0.01% | 3341 |
|
|
2017
Q1 | $307K | Buy |
74,199
+46,142
| +164% | +$194K | ﹤0.01% | 3659 |
|
|
2016
Q4 | $121K | Buy |
28,057
+981
| +4% | +$6.34K | ﹤0.01% | 3866 |
|
|
2016
Q3 | $267K | Buy |
27,076
+5,124
| +23% | +$36.3K | ﹤0.01% | 3656 |
|
|
2016
Q2 | $125K | Sell |
21,952
-148,622
| -87% | -$1.01M | ﹤0.01% | 3834 |
|
|
2016
Q1 | $1.3M | Sell |
170,574
-66
| -0% | -$508 | ﹤0.01% | 3171 |
|
|
2015
Q4 | $2.27M | Buy |
170,640
+6,001
| +4% | +$103K | ﹤0.01% | 2986 |
|
|
2015
Q3 | $2.71M | Buy |
164,639
+2,361
| +1% | +$48.4K | ﹤0.01% | 2854 |
|
|
2015
Q2 | $3.64M | Buy |
162,278
+15,384
| +10% | +$243K | ﹤0.01% | 2720 |
|
|
2015
Q1 | $1.44M | Buy |
146,894
+3,875
| +3% | +$38K | ﹤0.01% | 3281 |
|
|
2014
Q4 | $1.63M | Buy |
143,019
+16,609
| +13% | +$180K | ﹤0.01% | 3217 |
|
|
2014
Q3 | $1.46M | Buy |
126,410
+96,366
| +321% | +$1.47M | ﹤0.01% | 3278 |
|
|
2014
Q2 | $584K | Buy |
30,044
+12,604
| +72% | +$222K | ﹤0.01% | 3557 |
|
|
2014
Q1 | $313K | Sell |
17,440
-1,059
| -6% | -$17.4K | ﹤0.01% | 3668 |
|
|
2013
Q4 | $195K | Buy |
18,499
+3,829
| +26% | +$42.8K | ﹤0.01% | 3724 |
|
|
2013
Q3 | $181K | Sell |
14,670
-78,206
| -84% | -$823K | ﹤0.01% | 3684 |
|
|
2013
Q2 | $874K | Buy |
+92,876
| New | +$1.19M | ﹤0.01% | 3308 |
|
Northern Trust's CASC Position: Q1 2018 in Review
Northern Trust sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 391,781 shares — an estimated $1.45M sold.
Northern Trust first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $3.64M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Northern Trust reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Northern Trust sold 391,781 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $1.45M.
- Northern Trust first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Northern Trust's Cascadian Therapeutics, Inc. position peaked at $3.64M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Northern Trust's 13F filing for Q1 2018, filed 9 May 2018.